CN110520158A - 用于增强抗体介导的受体信号传导的组合物和方法 - Google Patents

用于增强抗体介导的受体信号传导的组合物和方法 Download PDF

Info

Publication number
CN110520158A
CN110520158A CN201880010285.3A CN201880010285A CN110520158A CN 110520158 A CN110520158 A CN 110520158A CN 201880010285 A CN201880010285 A CN 201880010285A CN 110520158 A CN110520158 A CN 110520158A
Authority
CN
China
Prior art keywords
amino acid
polypeptide
antibody
region
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880010285.3A
Other languages
English (en)
Chinese (zh)
Inventor
韦恩·A·马拉斯科
朱铨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CN110520158A publication Critical patent/CN110520158A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880010285.3A 2017-02-06 2018-02-06 用于增强抗体介导的受体信号传导的组合物和方法 Pending CN110520158A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455245P 2017-02-06 2017-02-06
US62/455,245 2017-02-06
PCT/US2018/017027 WO2018145075A1 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling

Publications (1)

Publication Number Publication Date
CN110520158A true CN110520158A (zh) 2019-11-29

Family

ID=63040120

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880010285.3A Pending CN110520158A (zh) 2017-02-06 2018-02-06 用于增强抗体介导的受体信号传导的组合物和方法

Country Status (7)

Country Link
US (2) US20220213206A1 (https=)
EP (1) EP3576793A4 (https=)
JP (3) JP7231549B2 (https=)
CN (1) CN110520158A (https=)
AU (2) AU2018215673B2 (https=)
CA (1) CA3049689A1 (https=)
WO (1) WO2018145075A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900500TA (en) * 2016-07-22 2019-02-27 Dana Farber Cancer Inst Inc Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MD4324851T2 (ro) 2018-07-19 2025-12-31 Regeneron Pharma Receptori antigenici chimerici cu specificitate BCMA și utilizările acestora
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
US20240239905A1 (en) * 2021-05-13 2024-07-18 Arizona Board Of Regents On Behalf Of Arizona State University A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer
CN115873126A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 人生长激素融合蛋白及其制备和用途
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
KR20250099103A (ko) 2022-08-15 2025-07-01 다나-파버 캔서 인스티튜트 인크. Cldn4에 대한 항체 및 이의 사용 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031020A1 (en) * 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
AU2015200990A1 (en) * 2009-03-20 2015-03-19 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
WO2016071376A2 (en) * 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
WO2016139365A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2016164480A1 (en) * 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
BR112015000167B1 (pt) * 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
KR20200024345A (ko) * 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
JO3568B1 (ar) * 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
JP7269167B2 (ja) * 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
SG11201903693QA (en) * 2016-11-01 2019-05-30 Genmab Bv Polypeptide variants and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031020A1 (en) * 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
AU2015200990A1 (en) * 2009-03-20 2015-03-19 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
WO2016071376A2 (en) * 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
WO2016139365A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2016164480A1 (en) * 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use

Also Published As

Publication number Publication date
AU2025202811A1 (en) 2025-05-08
US20240336694A1 (en) 2024-10-10
CA3049689A1 (en) 2018-08-09
EP3576793A4 (en) 2021-03-31
JP2020505054A (ja) 2020-02-20
AU2018215673B2 (en) 2025-01-23
EP3576793A1 (en) 2019-12-11
JP2025028191A (ja) 2025-02-28
JP7231549B2 (ja) 2023-03-01
WO2018145075A1 (en) 2018-08-09
AU2025202811A9 (en) 2026-03-05
AU2018215673A1 (en) 2019-07-25
JP2023036899A (ja) 2023-03-14
US20220213206A1 (en) 2022-07-07
JP7606501B2 (ja) 2024-12-25

Similar Documents

Publication Publication Date Title
US20240336694A1 (en) Compositions and methods for augmenting antibody mediated receptor signaling
US20250066481A1 (en) Fc variant compositions and methods of use thereof
US10519234B2 (en) NKp46 binding proteins
JP2022513432A (ja) 免疫細胞活性化のための二重特異性抗体
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
JP2017504328A (ja) 二重特異性ｃｄ３及びｃｄ１９抗原結合構築物
JP2020511997A (ja) 腫瘍抗原提示誘導物質構築物及びその使用
US20200325232A1 (en) Multispecific antigen binding proteins
JP7715722B2 (ja) 抗ｃｄ１３７コンストラクト及びその使用
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
JP2025540657A (ja) 抗ｃｄ３抗体
US20240132593A1 (en) Anti-vista antibodies and uses thereof
RU2819624C2 (ru) Композиции анти-cd112r антител и сопутствующие способы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination